Invivyd vs Intellia Therapeutics
Intellia Therapeutics is the larger business, with $67.7m of revenue in fiscal 2025 against $53.4m for Invivyd (1.3 times as much). Invivyd grew faster (110.5% against 16.9%). Invivyd kept more of each dollar of sales as profit: a net margin of -98.2% against -609.9%. Invivyd carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | InvivydIVVD, 2025 | Intellia TherapeuticsNTLA, 2025 |
|---|---|---|
| Revenue | $53.4m | $67.7m |
| Revenue growth | 110.5% | 16.9% |
| Net income | −$52.5m | −$413m |
| Operating margin | -104.0% | -651.7% |
| Net margin | -98.2% | -609.9% |
| Return on equity | -34.0% | -53.5% |
| Free cash flow | −$58.3m | −$396m |
| Cash | $227m | $155m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 122 | 377 |
| Market value | $169m | $1.65bn |
| Price vs our value range | — | — |
| Moat score | — | 8 (Weak) |
| Insider trades, 12 months | 1 buys, 20 sales | 1 buys, 18 sales |